Furthermore, a phase 2 trial showed that survodutide, a dual GLP-1 and glucagon receptor agonist, improved MASH without aggravating fibrosis, highlighting its potential as a future therapy [245]. This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.